Abstract
Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Current Pharmaceutical Design
Title:Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Volume: 19 Issue: 32
Author(s): Miriam Ojeda-Ojeda, Mora Murri, Maria Insenser and Hector F. Escobar-Morreale
Affiliation:
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Abstract: Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Export Options
About this article
Cite this article as:
Ojeda-Ojeda Miriam, Murri Mora, Insenser Maria and Escobar-Morreale F. Hector, Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS), Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320012
DOI https://dx.doi.org/10.2174/1381612811319320012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An NMR Metabolomic Study in the Old Order Amish to Study Increased Dietary Salt Associated with Elevation of Organic Osmolytes Detected in Urine
Current Metabolomics The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Infective Endocarditis Complicating Hypertrophic Obstructive Cardiomyopathy: Is Antibiotic Prophylaxis Really Unnecessary?
Current Cardiology Reviews Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Diabetes in Racial and Ethnic Minorities in the United States: Individualizing Approaches to Diagnosis and Management
Current Diabetes Reviews Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Current Pharmaceutical Design Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?
Current Diabetes Reviews Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry Incidence of Type 2 Diabetes Among Patients Exposed to the Combination of Pravastatin and Paroxetine
Current Drug Safety Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Rapid Non-genomic Vasodilator Actions of Oestrogens and Sex Steroids
Current Medicinal Chemistry